Utah Medical Products (UTMD) Cost of Revenue (2010 - 2026)

Utah Medical Products' Cost of Revenue history runs 17 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• On a quarterly basis, Cost of Revenue fell 17.55% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $15.8 million, a 3.48% decrease from a year earlier, with the FY2025 full-year figure at $16.5 million, down 1.44% from the prior year.
• Cost of Revenue declined to $3.4 million in Q1 2026 per UTMD's latest filing, from $3.8 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $5.3 million in Q2 2022 and bottomed at $3.4 million in Q1 2026.
• The 5-year median for Cost of Revenue is $4.6 million (2024), against an average of $4.5 million.
• Across the five-year window, Cost of Revenue rose 19.24% in 2022 and retreated 26.74% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $5.2 million in 2022, then slipped by 0.23% to $5.2 million in 2023, then fell by 26.74% to $3.8 million in 2024, then declined by 1.41% to $3.8 million in 2025, then fell by 9.02% to $3.4 million in 2026.
• Per Business Quant, the three latest UTMD Cost of Revenue figures stand at $3.4 million (Q1 2026), $3.8 million (Q4 2025), and $4.2 million (Q3 2025).